Cargando…
Unmasking molecular profiles of bladder cancer
Precision medicine is designed to tailor treatments for individual patients by factoring in each person's specific biology and mechanism of disease. This paradigm shifted from a “one size fits all” approach to “personalized and precision care” requires multiple layers of molecular profiling of...
Autores principales: | Piao, Xuan-Mei, Byun, Young Joon, Kim, Wun-Jae, Kim, Jayoung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Urological Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840121/ https://www.ncbi.nlm.nih.gov/pubmed/29520382 http://dx.doi.org/10.4111/icu.2018.59.2.72 |
Ejemplares similares
-
Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist
por: Kim, Jayoung, et al.
Publicado: (2020) -
Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer
por: Kim, Ye-Hwan, et al.
Publicado: (2016) -
Role of Exosomal miRNA in Bladder Cancer: A Promising Liquid Biopsy Biomarker
por: Piao, Xuan-Mei, et al.
Publicado: (2021) -
Prominence of urinary biomarkers for bladder cancer in the COVID-19 era: From the commercially available to new prospective candidates
por: Piao, Xuan-Mei, et al.
Publicado: (2021) -
Identification of differentially expressed miRNAs and miRNA-targeted genes in bladder cancer
por: Lee, Jong-Young, et al.
Publicado: (2018)